MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation

European Journal of Neuroscience

Volumn 23, Issue 10, 2006, Pages 2669-2676

  Bishop, Christopher ^a   Taylor, Jennifer L ^b   Kuhn, Donald M ^b   Eskow, Karen L ^a   Park, John Y ^a   Walker, Paul D ^b  

^a BINGHAMTON UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; Basal ganglia; Dopamine; Rat; Serotonin; WAY100635

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENSERAZIDE; FENFLURAMINE; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; DYSKINESIA; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FENFLURAMINE; LEVODOPA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGENTS;

EID: 33744478909     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2006.04790.x     Document Type: Article

References (61)

1. Ahlskog, J.E. Muenter, M.D. 2001 Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord., 16, 448 458.
2. Antonelli, T., Fuxe, K., Tomasini, M.C., Bartoszyk, G.D., Seyfried, C.A., Tanganelli, S. Ferraro, L. 2005 Effects of sarizotan on the corticostriatal glutamate pathways. Synapse, 58, 193 199.
3. Balcioglu, A. Wurtman, R.J. 1998a Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals. Brain Res., 813, 67 72.
4. Balcioglu, A. Wurtman, R.J. 1998b Dexfenfluramine enhances striatal dopamine release in conscious rats via a serotoninergic mechanism. J. Pharmacol. Exp. Ther., 284, 991 997.
5. Bankson, M.G. Cunningham, K.A. 2001 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J. Pharmacol. Exp. Ther., 297, 846 852.
6. Bara-Jimenez, W., Bibbiani, F., Morris, M.J., Dimitrova, T., Sherzai, A., Mouradian, M.M. Chase, T.N. 2005 Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord., 20, 932 936.
7. Basura, G.J. Walker, P.D. 1999 Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation. Brain Res. Dev. Brain Res., 116, 111 117.
8. Battaglia, G., Brooks, B.P., Kulsakdinun, C. De Souza, E.B. 1988 Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol., 149, 159 163.
9. Berger, U.V., Gu, X.F. Azmitia, E.C. 1992 The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol., 215, 153 160.
10. Bibbiani, F., Oh, J.D. Chase, T.N. 2001 Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology, 57, 1829 1834.
11. Bishop, C., Tessmer, J.L., Ullrich, T., Rice, K.C. Walker, P.D. 2004 Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J. Pharmacol. Exp. Ther., 310, 687 694.
12. Bishop, C. Walker, P.D. 2003 Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience, 121, 649 657.
13. Castaneda, E., Fleming, S., Paquette, M.A., Boat, K., Moffett, J., Stachowiak, E.K., Bloom, D.C. Stachowiak, M.K. 2005 Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate. Physiol. Behav., 84, 525 535.
14. Celada, P., Puig, M.V., Casanovas, J.M., Guillazo, G. Artigas, F. 2001 Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABAA, and glutamate receptors. J. Neurosci., 21, 9917 9929.
15. Cenci, M.A., Lee, C.S. Bjorklund, A. 1998 L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694 2706.
16. Cenci, M.A., Whishaw, I.Q. Schallert, T. 2002 Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci., 3, 574 579.
17. Colado, M.I., O'Shea, E. Green, A.R. 2004 Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl.), 173, 249 263.
18. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D. Schaff, H.V. 1997 Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med., 337, 581 588.
19. Crespi, D., Mennini, T. Gobbi, M. 1997 Carrier-dependent and Ca (2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br. J. Pharmacol., 121, 1735 1743.
20. Durif, F., Vidailhet, M., Bonnet, A.M., Blin, J. Agid, Y. 1995 Levodopa-induced dyskinesias are improved by fluoxetine. Neurology, 45, 1855 1858.
21. Esteban, B., O'Shea, E., Camarero, J., Green, A.R. Colado, M.I. 2001 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology, 154, 251 260.
22. Fox, S.H. Brotchie, J.M. 2000 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord., 15, 1064 1069.
23. Fox, S.H., Moser, B. Brotchie, J.M. 1998 Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol., 151, 35 49.
24. Frechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., Luquin, M. Del Rio, J. 2001 Serotonin 5-HT (1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse, 39, 288 296.
25. Gozlan, H., Thibault, S., Laporte, A.M., Lima, L. Hamon, M. 1995 The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur. J. Pharmacol., 288, 173 186.
26. Green, A.R., Mechan, A.O., Elliott, J.M., O'Shea, E. Colado, M.I. 2003 The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol. Rev., 55, 463 508.
27. Hagell, P. Widner, H. 1999 Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov. Disord., 14, 448 455.
28. Hjorth, S. Sharp, T. 1991 Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci., 48, 1779 1786.
29. Iravani, M.M., Asari, D., Patel, J., Wieczorek, W.J. Kruk, Z.L. 2000 Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse, 36, 275 285.
30. Iravani, M.M., Jackson, M.J., Kuoppamaki, M., Smith, L.A. Jenner, P. 2003 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J. Neurosci., 23, 9107 9115.
31. Jackson, M.J., Al Barghouthy, G., Pearce, R.K., Smith, L., Hagan, J.J. Jenner, P. 2004 Effect of 5-HT (1B/D) receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav., 79, 391 400.
32. Kannari, K., Yamato, H., Shen, H., Tomiyama, M., Suda, T. Matsunaga, M. 2001 Activation of 5-HT (1A) but not 5-HT (1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem., 76, 1346 1353.
33. Kelly, R.M. Strick, P.L. 2004 Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog. Brain Res., 143, 449 459.
34. Kilpatrick, I.C., Jones, M.W. Phillipson, O.T. 1986 A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem., 46, 1865 1876.
35. Knobelman, D.A., Kung, H.F. Lucki, I. 2000 Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT (1A) and 5-HT (1B) receptors. J. Pharmacol. Exp. Ther., 292, 1111 1117.
36. Koch, S. Galloway, M.P. 1997 MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm., 104, 135 146.
37. Lowry, O.H., Rosebrough, N.J., Farr, A.L. Randall, R.J. 1951 Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265 275.
38. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. Cenci, M.A. 2002 Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Exp. J. Neurosci., 15, 120 132.
39. Maeda, T., Kannari, K., Shen, H., Arai, A., Tomiyama, M., Matsunaga, M. Suda, T. 2003 Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopamine denervation. Neurosci. Lett., 343, 17 20.
40. Maeda, T., Nagata, K., Yoshida, Y. Kannari, K. 2005 Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res., 1046, 230 233.
41. Martin-Ruiz, R. Ugedo, L. 2001 Electrophysiological evidence for postsynaptic 5-HT (1A) receptor control of dorsal raphe 5-HT neurones. Neuropharmacology, 41, 72 78.
42. Mignon, L. Wolf, W.A. 2002 Postsynaptic 5-HT (1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl.), 163, 85 94.
43. Mignon, L.J. Wolf, W.A. 2005 8-Hydroxy-2-(di-n-propylamino) tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport, 16, 699 703.
44. Miller, R. Beninger, R.J. 1991 On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog. Neurobiol., 36, 229 256.
45. Nicholson, S.L. Brotchie, J.M. 2002 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease- opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol., 9 (S3), 1 6.
46. Oh, J.D., Bibbiani, F. Chase, T.N. 2002 Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol., 177, 557 564.
47. Olanow, C.W., Damier, P., Goetz, C.G., Mueller, T., Nutt, J., Rascol, O., Serbanescu, A., Deckers, F. Russ, H. 2004 Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol., 27, 58 62.
48. Paxinos, G. Watson, W. 1998 The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press, San Diego.
49. Picconi, B., Pisani, A., Centonze, D., Battaglia, G., Storto, M., Nicoletti, F., Bernardi, G. Calabresi, P. 2003 Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain, 125, 2635 2645.
50. Porter, R.H., Benwell, K.R., Lamb, H., Malcolm, C.S., Allen, N.H., Revell, D.F., Adams, D.R. Sheardown, M.J. 1999 Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol., 128, 13 20.
51. Reader, T.A. Dewar, K.M. 1999 Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Neurochem. Int., 34, 1 21.
52. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L. Bland, S.T. 2000 CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 39, 777 787.
53. Schmidt, W.J., Mayerhofer, A., Meyer, A. Kovar, K.A. 2002 Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci. Lett., 330, 251 254.
54. Steece-Collier, K., Collier, T.J., Danielson, P.D., Kurlan, R., Yurek, D.M. Sladek, J.R. Jr. 2003 Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov. Disord., 18, 1442 1454.
55. Stocchi, F., Nordera, G. Marsden, C.D. 1997 Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin. Neuropharmacol., 20, 95 115.
56. Tanaka, Y., Kannari, T., Maeda, M., Tomiyama, T., Suda, M. Matsunaga, M. 1999 Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport, 10, 631 634.
57. Taylor, J.L., Bishop, C., Ullrich, T., Rice, K.C. Walker, P.D. 2006 Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology, 50, 761 768.
58. Taylor, J.L., Bishop, C. Walker, P.D. 2005 Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav., 81, 887 893.
59. Tintner, R. Jankovic, J. 2002 Treatment options for Parkinson's disease. Curr. Opin. Neurol., 15, 467 476.
60. Ungerstedt, U. 1971 Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand. Suppl., 367, 95 122.
61. Yamato, H., Kannari, K., Shen, H., Suda, T. Matsunaga, M. 2001 Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport, 12, 1123 1126.